Enjoy complimentary customisation on priority with our Enterprise License!
The smoking cessation and nicotine de-addiction market size is forecast to increase by USD 36.98 billion at a CAGR of 15.84% between 2023 and 2028. The market is experiencing significant growth due to several key trends. The rising adoption of online retailing for purchasing smoking cessation products is one such trend, as it offers convenience and accessibility to consumers. Additionally, new marketing initiatives, such as celebrity endorsements and social media campaigns, are increasing awareness about the health risks associated with smoking and the benefits of quitting. Furthermore, the health issues linked to smoking, including cancer, heart disease, and respiratory problems, continue to drive demand for effective smoking cessation solutions. These factors are expected to fuel market growth in the coming years.
Tobacco, a leading cause of chronic diseases worldwide, contains the addictive alkaloid nicotine. Neurotransmitters in the brain, particularly acetylcholine, are stimulated by nicotine, leading to feelings of pleasure and relaxation. Nicotine's addictive properties make quitting smoking a challenging process. Various nicotine replacement therapies (NRTs) are available, including nicotine lozenges, gums, sprays, and transdermal patches. Drug therapy options include Zyban (bupropion) and Chantix (varenicline), which target the neurotransmitter systems affected by nicotine. Non-nicotinic pharmacological therapies, such as cytisinicline (cytisine), are also being explored. The ORCA-3 study provides drug-class insights into the efficacy of these therapies. Behavioral therapies, including counseling and support groups, are also effective in smoking cessation. E-cigarettes, while marketed as a smoking cessation aid, contain harmful chemicals and are not recommended as a primary cessation method.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The drug stores and retailers segment is estimated to witness significant growth during the forecast period. The global market in 2023 is significantly influenced by the tobacco industry, with a high demand for nicotine replacement therapies (NRTs) such as nicotine lozenges, gums, sprays, transdermal patches, sublingual tablets, and inhalers. Neurotransmitters, including dopamine and acetylcholine, play a crucial role in nicotine addiction, making NRTs an effective solution for managing nicotine/tobacco dependence. Harmful chemicals in cigarettes contribute to chronic diseases like lung cancer, asthma, and cardiovascular diseases, driving the need for smoking cessation. Drug therapy is a primary approach to treating nicotine addiction, with emerging drugs like cytisine (Cytisinicline) showing promise in the ORCA-3 study. Drug Class Insights reveals that non-nicotinic pharmacological therapies and behavioral therapies are also gaining popularity.
Furthermore, NFL Biosciences and other companies are expanding their product offerings to cater to the diverse needs of consumers. The retail segment, including drug stores and retailers, dominates the market. However, the shift towards online shopping has led to a decline in sales. To counter this trend, companies are expanding their businesses into local and regional markets and selling their products through both specialty stores and other retail formats. Despite the challenges, the market is expected to grow due to the increasing awareness of the health risks associated with tobacco use and the availability of effective smoking cessation solutions.
Get a glance at the market share of various segments Request Free Sample
The drug stores and retailers segment was valued at USD 12.20 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 30% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
Tobacco use, primarily driven by nicotine addiction, remains a significant public health concern due to its association with chronic diseases such as lung cancer, asthma, and cardiovascular diseases. Nicotine, a highly addictive neurotransmitter found in tobacco, acts on the reward system of the brain, leading to irritability, anxiety, dysphoria, and hedonic dysregulation upon withdrawal. Nicotine replacement therapies (NRT), including nicotine lozenges, gums, sprays, transdermal patches, sublingual tablets, and inhalers, have emerged as effective tools for smoking cessation. Drug therapy, such as bupropion and varenicline, targets nicotine/tobacco dependence by modifying brain chemistry. Emerging drugs like cytisine, as shown in the ORCA-3 study, exhibit potential in nicotine addiction diagnosis and treatment.
Furthermore, drug Class Insights reveals that non-nicotinic pharmacological therapies and behavioral therapies are also gaining popularity. NFL Biosciences, for instance, is developing a novel nicotine antagonist for smoking cessation. Medicaid and Medicare cover various smoking cessation methods, expanding access to these treatments. Battery-powered devices like e-cigarettes, while controversial, are also used for nicotine delivery, though their long-term health effects are yet to be fully understood.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The rising adoption of online retailing is the key driver of the market. The Tobacco industry continues to grapple with the global health crisis caused by Nicotine and Harmful chemicals found in Tobacco products, leading to an increased focus on Smoking Cessation and Nicotine De-Addiction. Nicotine, a highly addictive substance, interacts with Neurotransmitters in the brain, causing Irritability, Anxiety, Dysphoria, and Hedonic dysregulation, leading to Nicotine addiction. Various Nicotine replacement therapies, such as Nicotine lozenges, Nicotine gums, Nicotine sprays, Nicotine transdermal patches, Nicotine sublingual tablets, and Nicotine inhalers, are widely used for Smoking cessation. Drug therapy, including Bupropion and Varenicline, is also an effective treatment. Emerging drugs like Cytisinicline (cytisine) are gaining popularity due to their efficacy in Nicotine/tobacco dependence treatment.
Furthermore, the ORCA-3 study demonstrated Cytisinicline's superiority over placebo in helping smokers quit. Non-nicotinic pharmacological therapies and Behavioral therapies are also effective, with NFL Biosciences' Nicotine antagonist, FDA-approved for Smoking cessation. Medicaid and Medicare cover Smoking cessation treatments, making them accessible to a larger population. E-cigarettes, although marketed as a Smoking cessation aid, contain nicotine and other harmful chemicals, posing health risks. Battery-powered devices, such as Gum, Inhaler, and Tablet, offer a safer alternative. As the global population becomes more health-conscious, the demand for effective Smoking cessation treatments is expected to increase.
The new marketing initiatives is the upcoming trend in the market. The global market is witnessing significant growth due to increasing awareness about the harmful effects of tobacco and nicotine on health. Nicotine, a highly addictive substance found in tobacco, interacts with neurotransmitters in the brain, leading to irritability, anxiety, dysphoria, and hedonic dysregulation upon withdrawal. To combat nicotine/tobacco dependence, various nicotine replacement therapies (NRTs) such as nicotine lozenges, gums, sprays, transdermal patches, sublingual tablets, and inhalers are available. Drug therapy, including bupropion and varenicline, is also used for nicotine addiction diagnosis and treatment. Emerging drugs like cytisine (Cytisinicline), as shown in the ORCA-3 study, are gaining attention in the market.
Furthermore, non-nicotinic pharmacological therapies and behavioral therapies are also being explored. companies are taking innovative marketing initiatives to promote these products. For instance, JUUL's first television ad campaign, titled "Taste Test Drive," featured testimonials from adults who have used JUUL products to quit smoking. Such campaigns, targeted at older smokers, aim to increase sales and boost the market growth during the forecast period. Medicaid and Medicare are also providing coverage for smoking cessation treatments, further driving market demand.
The health issues associated with smoking cessation products is a key challenge affecting the market growth. The market encompasses a range of products designed to aid in the cessation of nicotine/tobacco dependence, including nicotine lozenges, gums, sprays, transdermal patches, sublingual tablets, inhalers, and e-cigarettes. Neurotransmitters, specifically dopamine, play a significant role in nicotine addiction, making it challenging to quit. Harmful chemicals in cigarettes contribute to chronic diseases such as lung cancer, asthma, and cardiovascular diseases. Despite the market's potential growth, concerns regarding the long-term health effects of nicotine replacement therapies (NRTs) may hinder its progress. For instance, nicotine gums can lead to health issues like hair loss, skin irritation, elevated blood pressure, irregular heartbeat, insulin resistance, gastrointestinal problems, and nausea.
Furthermore, continuous chewing can result in dental problems. Nicotine patches present side effects such as skin irritation, itching, dizziness, and headache. Emerging drugs, such as cytisinicline (cytisine), are being explored as potential alternatives to traditional NRTs. The ORCA-3 study highlighted the efficacy of cytisine in smoking cessation. Drug therapy advancements and non-nicotinic pharmacological therapies are also gaining traction. Behavioral therapies, including NFL Biosciences' approaches, have shown promise in helping individuals quit smoking. Additionally, government programs like Medicaid and Medicare contribute to the market's growth by providing coverage for smoking cessation treatments.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Pfizer - The company's key offerings include smoking cessation and nicotine de-addiction guidance.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Tobacco use, primarily driven by nicotine addiction, remains a significant public health concern worldwide. Nicotine, a highly addictive neurotransmitter found in tobacco products, disrupts the balance of dopamine and acetylcholine in the brain, leading to irritability, anxiety, dysphoria, and hedonic dysregulation upon withdrawal. Smoking cessation is crucial to prevent chronic diseases, including lung cancer and asthma, caused by harmful chemicals in cigarettes. Nicotine replacement therapies (NRTs), such as nicotine lozenges, gums, sprays, transdermal patches, sublingual tablets, and inhalers, have emerged as effective tools for managing nicotine/tobacco dependence. Drug therapy, including nicotine receptor agonists and antagonists, is another approach. Emerging drugs like cytisinicline (cytisine) are showing promise in nicotine addiction diagnosis and treatment.
Furthermore, battery-powered devices, such as e-cigarettes, are increasingly popular as smoking cessation aids. Non-nicotinic pharmacological therapies and behavioral therapies are also being explored. For instance, the ORCA-3 study demonstrated the effectiveness of non-nicotinic pharmacological therapies in smoking cessation. Medicaid and Medicare are significant payers for smoking cessation treatments, driving market growth. Drug class insights and NLBiosciences are among the key players in the market.
Market Scope |
|
Report Coverage |
Details |
Page number |
176 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 15.84% |
Market Growth 2024-2028 |
USD 36.98 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
13.32 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 30% |
Key countries |
US, Germany, China, Canada, and India |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alchem International Pvt. Ltd., Alkalon AS, Alvogen Iceland ehf, Axcentria Pharmaceuticals, British American Tobacco Plc, Cambrex Corp., CHEMNOVATIC Sp. z o.o. Sp. k, Cipla Inc., Dr Reddys Laboratories Ltd., Enorama Pharma AB, Imperial Brands Plc, Japan Tobacco Inc., Johnson and Johnson Services Inc., Lil Drug Store Products Inc., Perrigo Co. Plc, Pfizer Inc., Philip Morris International Inc., Qnovia, Tvape, and Walgreens Boots Alliance Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.